The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer.
William Proctor Harris
No relevant relationships to disclose
Sunil R. Hingorani
No relevant relationships to disclose
Joseph Thaddeus Beck
No relevant relationships to disclose
Boris A. Berdov
No relevant relationships to disclose
Stephanie Ann Wagner
No relevant relationships to disclose
Eduard M. Pshevlotsky
No relevant relationships to disclose
Sergei Tjulandin
No relevant relationships to disclose
Oleg Gladkov
No relevant relationships to disclose
Randall F. Holcombe
No relevant relationships to disclose
Ping Jiang
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Daniel C. Maneval
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Joy Zhu
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Craig E. Devoe
No relevant relationships to disclose